DPM Stock Chart & Stats
€8.41
€0.06(0.84%)
At close: 4:00 PM EDT
€8.41
€0.06(0.84%)
Day’s Range― - ―
52-Week Range€6.65 - €18.80
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€4.06B
Enterprise Value€737.89K
Total Cash (Recent Filing)€76.64B
Total Debt (Recent Filing)€160.66B
Price to Earnings (P/E)5.5
Beta1.15
Next Earnings
Nov 04, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)279.80
Shares Outstanding449,204,560
10 Day Avg. Volume2
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.82
Price to Sales (P/S)1.82
P/FCF Ratio12.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.44Price Target Upside59.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.15
Revenue Forecast (FY)€3.03B
Bulls Say, Bears Say
Bulls Say
Profitability TurnaroundThe sharp return to strong profitability improves the company’s ability to fund research, commercialization, and debt reduction internally. Revenue growth alongside high gross and EBITDA margins suggests the current portfolio is generating meaningful operating leverage, supporting earnings capacity over the next several quarters.
Positive Free Cash FlowPositive free cash flow that closely tracks reported earnings provides tangible financial support for the turnaround. This cash generation can strengthen liquidity, finance pipeline investment, and reduce reliance on external funding, although maintaining it will be important given the company’s prior cash-flow volatility.
Improved Balance-sheet LeverageMaterial deleveraging from earlier peaks reduces balance-sheet stress and improves financial flexibility. A stronger equity base gives management more capacity to support pharmaceutical development and absorb setbacks, while lower leverage should reduce the burden of financing obligations compared with recent periods.
Bears Say
Highly Volatile ProfitabilityThe large swing from deep losses to high profitability indicates that earnings have not yet demonstrated consistency across the cycle. Such volatility makes it harder to assess sustainable earnings power and can constrain long-term planning if portfolio performance or other drivers reverse.
Weak Debt-service Cash CoverageA low operating-cash-flow-to-debt coverage ratio indicates that recurring operations currently provide limited capacity to service outstanding obligations. This leaves less room for error if cash generation weakens and may restrict the funds available for research investment, acquisitions, or other strategic priorities.
Uncertain Durability Of Earnings ReboundThe possibility that recent profitability reflects one-off effects, portfolio changes, or cyclicality creates a meaningful sustainability risk. If those factors fade, margins and earnings could normalize materially, weakening the cash-generation and deleveraging benefits currently supporting the business.
Sumitomo Dainippon Pharma Co News
DPM FAQ
What was Sumitomo Dainippon Pharma Co Ltd’s price range in the past 12 months?
Sumitomo Dainippon Pharma Co Ltd lowest stock price was €6.65 and its highest was €18.80 in the past 12 months.
What is Sumitomo Dainippon Pharma Co Ltd’s market cap?
Sumitomo Dainippon Pharma Co Ltd’s market cap is €4.06B.
When is Sumitomo Dainippon Pharma Co Ltd’s upcoming earnings report date?
Sumitomo Dainippon Pharma Co Ltd’s upcoming earnings report date is Nov 04, 2026 which is in 55 days.
How were Sumitomo Dainippon Pharma Co Ltd’s earnings last quarter?
Sumitomo Dainippon Pharma Co Ltd released its earnings results on Jul 31, 2026. The company reported €0.21 earnings per share for the quarter, beating the consensus estimate of €0.103 by €0.107.
Is Sumitomo Dainippon Pharma Co Ltd overvalued?
According to Wall Street analysts Sumitomo Dainippon Pharma Co Ltd’s price is currently Undervalued.
Does Sumitomo Dainippon Pharma Co Ltd pay dividends?
Sumitomo Dainippon Pharma Co Ltd does not currently pay dividends.
What is Sumitomo Dainippon Pharma Co Ltd’s EPS estimate?
Sumitomo Dainippon Pharma Co Ltd’s EPS estimate is 0.13.
How many shares outstanding does Sumitomo Dainippon Pharma Co Ltd have?
Sumitomo Dainippon Pharma Co Ltd has 449,204,560 shares outstanding.
What happened to Sumitomo Dainippon Pharma Co Ltd’s price movement after its last earnings report?
Sumitomo Dainippon Pharma Co Ltd reported an EPS of €0.21 in its last earnings report, beating expectations of €0.103. Following the earnings report the stock price went down -0.059%.
Which hedge fund is a major shareholder of Sumitomo Dainippon Pharma Co Ltd?
Currently, no hedge funds are holding shares in DE:DPM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
DPM Company Deck
DPM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call highlighted promising developments in the oncology and regenerative medicine pipelines but was overshadowed by significant financial losses, decreased revenue across all segments, and underperformance of key products, leading to a revised downward financial forecast. The call focused on strategic adjustments to address market challenges and improve profitability.View all DE:DPM earnings summariesDPM Stock 12 Month Forecast
Average Price Target
€13.44
▲(59.81% Upside)
Technical Analysis
Eisai Co
―
Kissei Pharmaceutical Co
―
Shionogi & Co
―
Takeda Pharmaceutical Co
―
Nippon Shinyaku Co., Ltd.
―